NCT01871961

Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient

Evaluation of Rheumatoid Arthritis Patient Performance Using the Metoject® Prefilled Pen (Methotrexate 50 mg/mL, Prefilled Pen) for Subcutaneous Injection and Subsequent Pharmacokinetic Assessment of Drug Delivery

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 105 (actual)
• Sponsor: medac GmbH · Industry
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).

Conditions

• Rheumatoid Arthritis (RA)

Interventions

Type	Name	Description
DRUG	Methotrexate (Metoject® prefilled pen)

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-02-01
• Completion: 2013-05-01
• First posted: 2013-06-07
• Last updated: 2015-03-17

Locations

1 site across 1 country: United States